{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:22:25Z","timestamp":1791440545642,"version":"4.3.3"},"reference-count":106,"publisher":"Korean Association for the Study of Intestinal Diseases","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["irjournal.org"],"crossmark-restriction":true},"short-container-title":["Intest Res"],"published-print":{"date-parts":[[2026,1,31]]},"abstract":"<jats:p>Inflammatory bowel disease (IBD), encompassing Crohn\u2019s disease (CD) and ulcerative colitis, is a chronic condition marked by immune dysregulation, genetic predisposition, and metabolic disturbances. Emerging evidence highlights the role of lipid metabolism and peroxisome proliferator-activated receptor (PPAR) signaling in modulating immune responses in IBD. PPAR-\u03b3 and PPAR-\u03b1 regulate macrophage polarization, T-cell differentiation, and epithelial barrier integrity, influencing disease severity and progression. Alterations in PPAR activity contribute to metabolic stress and inflammation, linking IBD pathophysiology to immunometabolism. Studies suggest that targeting PPARs may mitigate inflammation through modulation of cytokine production, immune cell function, and gut microbiota interactions. In this review, we focus specifically on CD and explore how PPAR signaling intersects with mesenteric adipose tissue dysfunction and microbial dysbiosis, 2 hallmark features of CD. PPAR agonists, already used in metabolic-inflammatory diseases such as metabolic-associated liver disease, have demonstrated antiinflammatory effects in experimental colitis models. Translating these findings into clinical applications could offer novel treatment strategies for CD. Future research should focus on clinical trials, genetic studies, and microbiota-targeted approaches to elucidate PPAR-driven mechanisms in CD pathogenesis. Understanding the interplay between PPARs, lipid metabolism, and immune responses may lead to innovative therapeutic strategies, improving disease management and patient outcomes.<\/jats:p>","DOI":"10.5217\/ir.2025.00090","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T04:32:52Z","timestamp":1754886772000},"page":"11-26","update-policy":"https:\/\/doi.org\/10.5217\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Peroxisome proliferator-activated receptors in inflammatory bowel disease: linking immunometabolism, lipid signaling, and therapeutic potential"],"prefix":"10.5217","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-9925","authenticated-orcid":true,"given":"Kiandokht","family":"Bashiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-1607","authenticated-orcid":true,"given":"Mark C.","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-2647","authenticated-orcid":true,"given":"Alireza","family":"Meighani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0470-9522","authenticated-orcid":true,"given":"Andrew L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3168","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02586-2"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00730"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03168-4"},{"key":"ref4","first-page":"452","volume-title":"Update in lean metabolic dysfunction-associated steatotic liver disease","author":"Sato-Espinoza","year":"2024"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22030985"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154338"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108176"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112367"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0020294"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312100"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cells13201688"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16978"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167326"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040650"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac266"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071029"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501489"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001454"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2010.12.059"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/nu10101499"},{"key":"ref21","first-page":"756","volume-title":"Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene","author":"Beamer","year":"1997"},{"key":"ref22","first-page":"8839","volume-title":"PPAR-\u03b3 with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD","author":"Vetuschi","year":"2018"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01070"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2010.75"},{"key":"ref25","volume-title":"","year":"Kristek M."},{"key":"ref26","first-page":"60","volume-title":"The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease","author":"Guri","year":"2010"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200209000-00004"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010215"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.081745"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0627-4"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-128736"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00318"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000000618"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2017.02.010"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt245"},{"key":"ref36","first-page":"1205","volume-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma","author":"Rousseaux","year":"2005"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(03)00271-3"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21322"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3397"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115119"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030551"},{"key":"ref42","first-page":"433","volume-title":"Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene in inflammatory bowel disease","author":"Atug","year":"2008"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/613864"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168969"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214156"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910545"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110368"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-019-01231-1"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01757-9"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2007.02.013"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.08.005"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00064"},{"key":"ref53","first-page":"2181928","volume-title":"Intestinal group 1 innate lymphoid cells drive macrophage-induced inflammation and endocrine defects in obesity and promote insulinemia","author":"Li\u00e9bana-Garc\u00eda","year":"2023"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105305"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12907"},{"key":"ref56","first-page":"15","volume-title":"The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the antiinflammatory actions of palmitoylethanolamide","author":"Lo Verme","year":"2005"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/futurepharmacol3040058"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618365"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf077"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.113"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00153.2014"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s490772"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113339"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109628"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.004"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216427"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn2717"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02403-1"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68347-x"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02313-2"},{"key":"ref71","first-page":"397","volume-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","author":"Hirschfield","year":"2023"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050793"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115338"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00072"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam9949"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020387"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad095"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12349"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2007.581"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071620"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy331"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958801"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0957-8"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701148"},{"key":"ref85","first-page":"283","volume-title":"Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade","author":"Takagi","year":"2002"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.03.024"},{"key":"ref87","first-page":"396","volume-title":"Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats","author":"Kohno","year":"2001"},{"key":"ref88","first-page":"113","volume-title":"Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells","author":"Hosokawa","year":"2004"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12050457"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy089"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16929"},{"key":"ref92","first-page":"169","volume-title":"Involvement of 5HT3 receptors in anti-inflammatory effects of tropisetron on experimental TNBS-induced colitis in rat","author":"Motavallian","year":"2013"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8430614"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109162"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.01.016"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1017\/s0007114516004189"},{"key":"ref97","first-page":"6079101","volume-title":"Extract attenuates development of dextran sulfate sodium induced colitis in mice through activation of PPAR","author":"Kong","year":"2018"},{"key":"ref98","first-page":"49","volume-title":"In vitro evaluation of the phytopharmacological potential of for the treatment of inflammatory bowel diseases","author":"Nyambe","year":"2019"},{"key":"ref99","first-page":"645","volume-title":"Tetramethylpyrazine attenuates PPAR-\u03b3 antagonist-deteriorated oxazolone-induced colitis in mice","author":"He","year":"2012"},{"key":"ref100","first-page":"917312","volume-title":"PPAR-alpha contributes to the anti-inflammatory activity of verbascoside in a model of inflammatory bowel disease in mice","author":"Esposito","year":"2010"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01277"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.3390\/cells13151296"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2018.06.009"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082033"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3450"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102358"}],"container-title":["Intestinal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/irjournal.org\/upload\/pdf\/ir-2025-00090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/irjournal.org\/journal\/view.php?doi=10.5217\/ir.2025.00090","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/irjournal.org\/upload\/pdf\/ir-2025-00090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T01:10:47Z","timestamp":1770167447000},"score":1,"resource":{"primary":{"URL":"http:\/\/irjournal.org\/journal\/view.php?doi=10.5217\/ir.2025.00090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"URL":"https:\/\/doi.org\/10.5217\/ir.2025.00090","relation":{},"ISSN":["1598-9100","2288-1956"],"issn-type":[{"value":"1598-9100","type":"print"},{"value":"2288-1956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"2025-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}